Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Angina V: Nursing Management

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Myocarditis IV: Nursing Management

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mapping illegal trade routes of live cheetahs from the Horn of Africa to the Arabian Peninsula.

Conservation biology : the journal of the Society for Conservation Biology·2024

Same author

What evidence exists on the links between natural climate solutions and climate change mitigation outcomes in subtropical and tropical terrestrial regions? A systematic map protocol.

Environmental evidence·2024

Same author

Water utility engagement in wildfire mitigation in watersheds in the western United States.

Journal of environmental management·2023

Same author

Identifying socioeconomic and biophysical factors driving forest loss in protected areas.

Conservation biology : the journal of the Society for Conservation Biology·2023

Same author

What evidence exists on the links between natural climate solutions and climate change mitigation outcomes in subtropical and tropical terrestrial regions? A systematic map protocol.

Environmental evidence·2022

Same author

What happens when the money runs out? Forest outcomes and equity concerns following Ecuador's suspension of conservation payments.

World development·2020

Search research articles

Related Experiment Video

Updated: May 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Do patients on statins also need niacin?

Kelly W Jones¹

¹Family Medicine Center, Florence, South Carolina, USA.

JAAPA : Official Journal of the American Academy of Physician Assistants

|August 8, 2013

Summary

This summary is machine-generated.

Niacin may not effectively lower cardiovascular disease risk in high-risk patients. It should be reserved for those who cannot tolerate or respond to statins, and never used if LDL cholesterol goals are met.

Related Experiment Videos

Last Updated: May 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiology
Pharmacology
Metabolic Disorders

Background:

Niacin (nicotinic acid) is a long-standing treatment for hypercholesterolemia.
Its efficacy in reducing cardiovascular disease (CVD) risk, particularly in high-risk populations, is under scrutiny.

Purpose of the Study:

To evaluate the current role of niacin in managing dyslipidemia and preventing CVD.
To provide guidance on niacin's appropriate use in contemporary clinical practice.

Main Methods:

Review of existing clinical trial data and meta-analyses on niacin's effects on lipid profiles and cardiovascular outcomes.
Analysis of niacin's benefits versus risks in different patient subgroups, including those with high CVD risk and those on statin therapy.

Main Results:

Niacin's benefit in reducing major cardiovascular events may be less pronounced than previously assumed, especially in high-risk patients.
Combination therapy with statins has not consistently shown added benefit in preventing cardiovascular events.
Niacin use is associated with potential side effects, including flushing and increased blood glucose levels.

Conclusions:

Niacin's role in treating hypercholesterolemia requires re-evaluation, particularly for high-risk individuals.
Current evidence suggests niacin should be reserved for patients intolerant to or unresponsive to statin therapy.
Niacin should not be used in patients who have already achieved their target low-density lipoprotein cholesterol levels with statins.